Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion OyjSTU:OFK -3.25%83 3-Year EBITDA Growth Rate is 12.30% as of Jun. 2026, which is 846% above its 10-year median of 1.30. GuruFocus rates STU:OFK with a GF Score™ of 83/100 and a GF Value™ of €74.38 (Fairly Valued). The stock has 4 warning signs investors should review. Among 809 Drug Manufacturers companies, Orion Oyj ranks better than 57.6% on this metric.
During the past 12 months, Orion Oyj's average EBITDA Per Share Growth Rate was 55.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 12.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 15.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 6.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Orion Oyj was 31.70% per year. The lowest was -4.60% per year. And the median was 1.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Orion Oyj 3-Year EBITDA Growth Rate Related Terms
STU:OFK vs LLY, JNJ, ABBV: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Orion Oyj's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Oyj 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Oyj's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Orion Oyj's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 12.30% mean?
Orion Oyj (STU:OFK) has a 3-Year EBITDA Growth Rate of 12.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Orion Oyj and its competitors. This is 846% above median its historical median of 1.30. According to the industry distribution chart, Orion Oyj ranks #343 out of 809 companies in the Drug Manufacturers industry, placing it in the top 42.4%.
Is Orion Oyj's 3-Year EBITDA Growth Rate too high?
Orion Oyj's current 3-Year EBITDA Growth Rate of 12.30% is 846% above median its 10-year median of 1.30. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Orion Oyj's value of 12.30% is 38.2% above this industry median. Based on the distribution chart, Orion Oyj ranks #343 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Orion Oyj has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orion Oyj's 3-Year EBITDA Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Orion Oyj ranks #343 out of 809 companies for 3-Year EBITDA Growth Rate. This puts Orion Oyj in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Orion Oyj's value of 12.30% is 38.2% above this benchmark. While the company's 10-year median is 1.30 vs. the industry median of 8.90, Orion Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Oyj's current 3-Year EBITDA Growth Rate of 12.30% is 38.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Orion Oyj and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Oyj's current 3-Year EBITDA Growth Rate is 12.30%, which is 846% above median its own 10-year median of 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Oyj stock overvalued right now?
Based on GuruFocus' analysis, Orion Oyj (STU:OFK) is currently considered Fairly Valued. The stock's GF Value™ is €74.38, compared to a current price of €78.90 — trading 6.1% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 12.30%, which is 846% above median its 10-year median of 1.30 and 38.2% above the Drug Manufacturers industry median of 8.90. Orion Oyj's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Orion Oyj (STU:OFK), the current 3-Year EBITDA Growth Rate is 12.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Oyj (STU:OFK) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Oyj stock appears to be overvalued.
The current stock price of €78.90 is trading 6.1% above its estimated GF Value™ of €74.38.
GuruFocus considers Orion Oyj to be Fairly Valued.
Key valuation signals for STU:OFK:
3-Year EBITDA Growth Rate: 12.30% (846% above median its 10-year median of 1.30)
GF Value™: €74.38 vs. price of €78.90 (6.1% above fair value)
Industry Position: 38.2% above the Drug Manufacturers median (#343 of 809)
No single metric tells the full story. See the STU:OFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
83GF Score
Get the complete analysis for STU:OFK
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:OFK has been successfully added to your 
